EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy

Camilla De Carlo, Reha Akpinar, Barbara Durante, Tiziana Pressiani, Julien Calderaro, Salvatore Lorenzo Renne, Angelo Pirozzi, Elena Valenzi, Irene Oi-Lin Ng, Tan To Cheung, Albino Eccher, Pamela Sighinolfi und 19 weitere

Liver Cancer · 19.09.2025 · 15 (3) · 394-407

DOI: 10.1159/000547669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 19.09.2025. Verfasst von Camilla De Carlo und 30 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Unit, IRCCS Humanitas Research Hospital, Milan, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Two distinct molecular groups of HCC have been recently associated with a better response to atezolizumab-bevacizumab. One of these, “angiogenesis-driven,” is related to HCC vascularization. Vessels that encapsulate tumor clusters (VETCs) is a morphological form of angiogenesis associated with worse prognosis in resected and transplanted HCC. The aim of this study was to explore if VETC can be used, at morphological level, to potentially surrogate the angiogenesis-driven molecular subgroup to identify HCC patients who might benefit of antiangiogenic treatments.

Methods

The significance of VETC was first explored in a retrospective, single institution series of 75 patients with unresectable HCC (study cohort) and later validated in an external, retrospective series of 82 patients (validation cohort). The VETC phenotype was identified in the liver biopsy obtained just before the onset of systemic treatment.

Results

Patients with VETC+ HCC experienced a significant survival benefit from antiangiogenic drugs, as tyrosine kinase inhibitors and/or bevacizumab (TKI/BEVA), across the study, validation, and overall cohorts. In the whole series of 157 patients, those with VETC+ HCC (n = 70, 45%) treated with TKI/BEVA had a significantly longer overall survival (OS) as compared to those receiving immune checkpoint inhibitors (19.8 months vs. 8.8 months; HR: 0.34; 95% CI: 0.20–0.59; p = 0.0001). The significant treatment-by-biomarker interaction test (p = 0.002) demonstrated that treatment effect varies by VETC status. Case with higher extent of VETC+ or with VETC+ detected before the onset of 1st-line treatment showed even longer survival.

Conclusion

VETC+ predicts a significantly longer OS in patients with unresectable HCC treated with TKI/BEVA and can be used as surrogate marker on liver biopsy of angiogenesis-driven molecular class.

Schlagwörter

Stichwörter der Autor:innen

Antiangiogenic treatmentBiomarkerHepatocellular carcinomaVessels that encapsulate tumor clusters

Autor:innen und Institutionen

  • Pathology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Pathology, Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), Créteil, France.
  • Department of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong SAR.
  • Department of Surgery and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong SAR.

Zitieren

APA

De Carlo, C., Akpinar, R., Durante, B., Pressiani, T., Calderaro, J., Renne, S. L., Pirozzi, A., Valenzi, E., Oi-Lin Ng, I., Cheung, T. T., Eccher, A., Sighinolfi, P., Villa, E., Iavarone, M., Maggioni, M., Shao, Y. Y., Lonardi, S., Rizzato, M. D., De Rosa, A., …, & Di Tommaso, L. (2025). Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy. Liver Cancer, 15(3), 394-407. https://doi.org/10.1159/000547669

Vancouver

De Carlo C, Akpinar R, Durante B, Pressiani T, Calderaro J, Renne SL, et al. Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy. Liver Cancer. 2025;15(3):394-407. doi:10.1159/000547669

BibTeX
@article{DeCarlo2025,
  author = {De Carlo, Camilla and Akpinar, Reha and Durante, Barbara and Pressiani, Tiziana and Calderaro, Julien and Renne, Salvatore Lorenzo and Pirozzi, Angelo and Valenzi, Elena and Oi-Lin Ng, Irene and Cheung, Tan To and Eccher, Albino and Sighinolfi, Pamela and Villa, Erica and Iavarone, Massimo and Maggioni, Marco and Shao, Yu-Yun and Lonardi, Sara and Rizzato, Mario Domenico and De Rosa, Antonio and Fassan, Matteo and Angerilli, Valentina and Pedica, Federica and Rimini, Margherita and Gardini, Andrea Casadei and Santoro, Armando and Park, Young Nyun and Roncalli, Massimo and Terracciano, Luigi and Piscuoglio, Salvatore and Rimassa, Lorenza and Di Tommaso, Luca},
  title = {Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy},
  journal = {Liver Cancer},
  year = {2025},
  volume = {15},
  number = {3},
  pages = {394--407},
  doi = {10.1159/000547669}
}
Kostenlos starten →